Sermorelin
Sermorelin is the first 29 amino acids of native GHRH — the minimum sequence retaining full biological activity. It was FDA-approved as Geref in 1997 for pediatric growth hormone deficiency, then voluntarily withdrawn in 2008 (commercial, not safety reasons).1
Sermorelin at a glance
Sermorelin is the first 29 amino acids of native GHRH — the minimum sequence retaining full biological activity. It was FDA-approved as Geref in 1997 for pediatric growth hormone deficiency, then voluntarily withdrawn in 2008 (commercial, not safety reasons).1
Sermorelin’s short half-life (~10 minutes) is its strength: it produces a pulse very close to native GHRH physiology and allows somatostatin feedback to operate normally. This pulsatile architecture is why some clinicians prefer Sermorelin for adult GH restoration over longer-acting analogues.
Binds GHRH receptor with native potency and short half-life, allowing somatostatin to provide normal feedback.1
When physiologic rhythm matters more than peak amplitude, Sermorelin remains a first-line GHRH analogue.
What the research actually shows
Sermorelin has been studied across multiple modalities. The summaries below cite peer-reviewed sources; individual response varies and is not guaranteed.
Preserves the natural pulse architecture more faithfully than long-acting analogues.
GHRH analogues consistently increase slow-wave sleep in older adults.2
Gradual rise toward age-appropriate IGF-1 range.
Decades of pediatric use establish a baseline rarely matched in peptide pharmacology.3
Pairs cleanly with Ipamorelin or other ghrelin agonists.
Some clinical work on cognitive markers in older adults on GHRH therapy.4
Your consultation is complimentary. Our medical team reviews your goals, current treatments, and history before recommending anything.
How a Sermorelin protocol typically runs at Luxbae
Dosing, cadence, and delivery method are tailored to you. The outline below describes the most common variant; your provider personalizes based on labs, current treatments, and goals.
Baseline IGF-1 and history.
Nightly subcutaneous pre-sleep.
IGF-1 at 6–8 weeks.
Often paired with Ipamorelin for stronger pulse.
Frequently sequenced alongside
- IPA / Sermorelin Blend — the gentle stack.
- Standalone Ipamorelin for solo ghrelin.
- CJC-1295 if a longer half-life is preferred.
- Morpheus8 for collagen amplification.
Who it’s for — and who should avoid it
Sermorelin eligibility is confirmed during your medical consultation; your full medical history must be disclosed.
- Adults pursuing physiologic GH support.
- First-time GH peptide users.
- Patients valuing safety pedigree.
- No malignancy history.
- Pregnancy or breastfeeding.
- Children and adolescents.
- Acute infection or autoimmune flare.
- Known peptide hypersensitivity.
- Active or recent malignancy.
- Untreated severe sleep apnea.
- Active proliferative retinopathy.
Possible side effects
Injection-site reactions, transient flushing, occasional headache.
FDA & regulatory note
Sermorelin was FDA-approved (Geref) for pediatric GHD and withdrawn for commercial reasons in 2008. Current adult use is compounded and investigational.
Dr. Ernst von Schwarz, MD, PhD
Professor Dr. Ernst von Schwarz — triple board-certified clinical and academic cardiologist, clinical professor of medicine at UCLA, and a three-decade pioneer in stem cell and regenerative medicine research — personally directs Luxbae’s peptide program. He has authored more than 150 peer-reviewed scientific papers and lectures internationally on cardiovascular and regenerative medicine. Every Sermorelin protocol at Luxbae is prescribed and monitored under his direction.
Meet Dr. von SchwarzSermorelin FAQ
Why Sermorelin over CJC-1295?
Is the pediatric data relevant?
Best for new patients?
Daily injection?
Stack with Ipamorelin?
When to upgrade?
Clinical References
Reviewed by Dr. Ernst von Schwarz and the Luxbae medical team. Statements on this page are educational and supported by the following peer-reviewed sources. Individual results vary.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency. Clin Interv Aging. 2006;1(4):307-308. View
- Vitiello MV, Moe KE, Merriam GR, et al. Growth hormone releasing hormone increases sleep in older men. Sleep. 1997. View
- Thorner MO, Rivier J, Spiess J, et al. Human pancreatic growth-hormone-releasing factor selectively stimulates GH. Lancet. 1983. View
- Vitiello MV, Moe KE, et al. Cognitive effects of GHRH. J Clin Endocrinol Metab. 2006. View
Start your Sermorelin protocol at Luxbae West Hollywood
Your consultation is complimentary. We’ll walk you through how Sermorelin fits your goals, what labs (if any) we’d run, and how it would sequence with the rest of your aesthetic plan.